Skip to main content
Top
Published in: Intensive Care Medicine 10/2022

Open Access 23-08-2022 | Pharmacokinetics | Review

Machines that help machines to help patients: optimising antimicrobial dosing in patients receiving extracorporeal membrane oxygenation and renal replacement therapy using dosing software

Authors: Jason A. Roberts, Rinaldo Bellomo, Menino O. Cotta, Birgit C. P. Koch, Haifa Lyster, Marlies Ostermann, Claire Roger, Kiran Shekar, Kevin Watt, Mohd H. Abdul-Aziz

Published in: Intensive Care Medicine | Issue 10/2022

Login to get access

Abstract

Intensive care unit (ICU) patients with end-organ failure will require specialised machines or extracorporeal therapies to support the failing organs that would otherwise lead to death. ICU patients with severe acute kidney injury may require renal replacement therapy (RRT) to remove fluid and wastes from the body, and patients with severe cardiorespiratory failure will require extracorporeal membrane oxygenation (ECMO) to maintain adequate oxygen delivery whilst the underlying pathology is evaluated and managed. The presence of ECMO and RRT machines can further augment the existing pharmacokinetic (PK) alterations during critical illness. Significant changes in the apparent volume of distribution (Vd) and drug clearance (CL) for many important drugs have been reported during ECMO and RRT. Conventional antimicrobial dosing regimens rarely consider the impact of these changes and consequently, are unlikely to achieve effective antimicrobial exposures in critically ill patients receiving ECMO and/or RRT. Therefore, an in-depth understanding on potential PK changes during ECMO and/or RRT is required to inform antimicrobial dosing strategies in patients receiving ECMO and/or RRT. In this narrative review, we aim to discuss the potential impact of ECMO and RRT on the PK of antimicrobials and antimicrobial dosing requirements whilst receiving these extracorporeal therapies. The potential benefits of therapeutic drug monitoring (TDM) and dosing software to facilitate antimicrobial therapy for critically ill patients receiving ECMO and/or RRT are also reviewed and highlighted.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hites M, Dell’Anna AM, Scolletta S, Taccone FS (2014) The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients. Adv Drug Deliv Rev 77:12–21PubMedCrossRef Hites M, Dell’Anna AM, Scolletta S, Taccone FS (2014) The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients. Adv Drug Deliv Rev 77:12–21PubMedCrossRef
2.
go back to reference Cheng V, Abdul-Aziz MH, Roberts JA (2021) Applying antimicrobial pharmacokinetic principles for complex patients: critically ill adult patients receiving extracorporeal membrane oxygenation and renal replacement therapy. Curr Infect Dis Rep 23:13CrossRef Cheng V, Abdul-Aziz MH, Roberts JA (2021) Applying antimicrobial pharmacokinetic principles for complex patients: critically ill adult patients receiving extracorporeal membrane oxygenation and renal replacement therapy. Curr Infect Dis Rep 23:13CrossRef
3.
go back to reference Kuhn D, Metz C, Seiler F, Wehrfritz H, Roth S, Alqudrah M, Becker A, Bracht H, Wagenpfeil S, Hoffmann M, Bals R, Hubner U, Geisel J, Lepper PM, Becker SL (2020) Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study. Crit Care 24:664PubMedPubMedCentralCrossRef Kuhn D, Metz C, Seiler F, Wehrfritz H, Roth S, Alqudrah M, Becker A, Bracht H, Wagenpfeil S, Hoffmann M, Bals R, Hubner U, Geisel J, Lepper PM, Becker SL (2020) Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study. Crit Care 24:664PubMedPubMedCentralCrossRef
4.
go back to reference Roberts JA, Joynt GM, Lee A, Choi G, Bellomo R, Kanji S, Mudaliar MY, Peake SL, Stephens D, Taccone FS, Ulldemolins M, Valkonen MM, Agbeve J, Baptista JP, Bekos V, Boidin C, Brinkmann A, Buizen L, Castro P, Cole CL, Creteur J, De Waele JJ, Deans R, Eastwood GM, Escobar L, Gomersall C, Gresham R, Jamal JA, Kluge S, Konig C, Koulouras VP, Lassig-Smith M, Laterre PF, Lei K, Leung P, Lefrant JY, Llaurado-Serra M, Martin-Loeches I, Mat Nor MB, Ostermann M, Parker SL, Rello J, Roberts DM, Roberts MS, Richards B, Rodriguez A, Roehr AC, Roger C, Seoane L, Sinnollareddy M, Sousa E, Soy D, Spring A, Starr T, Thomas J, Turnidge J, Wallis SC, Williams T, Wittebole X, Zikou XT, Paul SK, Lipman J, Collaborators SS, the ACTG (2021) The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational sampling antibiotics in renal replacement therapy study. Clin Infect Dis 72:1369–1378PubMedCrossRef Roberts JA, Joynt GM, Lee A, Choi G, Bellomo R, Kanji S, Mudaliar MY, Peake SL, Stephens D, Taccone FS, Ulldemolins M, Valkonen MM, Agbeve J, Baptista JP, Bekos V, Boidin C, Brinkmann A, Buizen L, Castro P, Cole CL, Creteur J, De Waele JJ, Deans R, Eastwood GM, Escobar L, Gomersall C, Gresham R, Jamal JA, Kluge S, Konig C, Koulouras VP, Lassig-Smith M, Laterre PF, Lei K, Leung P, Lefrant JY, Llaurado-Serra M, Martin-Loeches I, Mat Nor MB, Ostermann M, Parker SL, Rello J, Roberts DM, Roberts MS, Richards B, Rodriguez A, Roehr AC, Roger C, Seoane L, Sinnollareddy M, Sousa E, Soy D, Spring A, Starr T, Thomas J, Turnidge J, Wallis SC, Williams T, Wittebole X, Zikou XT, Paul SK, Lipman J, Collaborators SS, the ACTG (2021) The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational sampling antibiotics in renal replacement therapy study. Clin Infect Dis 72:1369–1378PubMedCrossRef
5.
go back to reference Bougle A, Dujardin O, Lepere V, Ait Hamou N, Vidal C, Lebreton G, Salem JE, El-Helali N, Petijean G, Amour J (2019) PHARMECMO: therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. Anaesth Crit Care Pain Med 38:493–497PubMedCrossRef Bougle A, Dujardin O, Lepere V, Ait Hamou N, Vidal C, Lebreton G, Salem JE, El-Helali N, Petijean G, Amour J (2019) PHARMECMO: therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support. Anaesth Crit Care Pain Med 38:493–497PubMedCrossRef
6.
go back to reference Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I (2017) Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships. J Antimicrob Chemother 72:2891–2897PubMedCrossRef Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I (2017) Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships. J Antimicrob Chemother 72:2891–2897PubMedCrossRef
7.
go back to reference Abdul-Aziz MH, Driver E, Lipman J, Roberts JA (2018) New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods. Expert Opin Drug Metab Toxicol 14:693–708PubMedCrossRef Abdul-Aziz MH, Driver E, Lipman J, Roberts JA (2018) New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods. Expert Opin Drug Metab Toxicol 14:693–708PubMedCrossRef
8.
go back to reference Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, Timsit JF, Udy AA, Wicha SG, Zeitlinger M, De Waele JJ, Roberts JA, Infection Section of European Society of Intensive Care M, Pharmacokinetic/pharmacodynamic, Critically Ill Patient Study Groups of European Society of Clinical M, Infectious D, Infectious Diseases Group of International Association of Therapeutic Drug M, Clinical T, Infections in the ICU, Sepsis Working Group of International Society of Antimicrobial C (2020) Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med 46:1127–1153PubMedPubMedCentralCrossRef Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, Timsit JF, Udy AA, Wicha SG, Zeitlinger M, De Waele JJ, Roberts JA, Infection Section of European Society of Intensive Care M, Pharmacokinetic/pharmacodynamic, Critically Ill Patient Study Groups of European Society of Clinical M, Infectious D, Infectious Diseases Group of International Association of Therapeutic Drug M, Clinical T, Infections in the ICU, Sepsis Working Group of International Society of Antimicrobial C (2020) Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med 46:1127–1153PubMedPubMedCentralCrossRef
9.
go back to reference Tangden T, Ramos Martin V, Felton TW, Nielsen EI, Marchand S, Bruggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA (2017) The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med 43:1021–1032PubMedCrossRef Tangden T, Ramos Martin V, Felton TW, Nielsen EI, Marchand S, Bruggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA (2017) The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med 43:1021–1032PubMedCrossRef
10.
11.
go back to reference Udy AA, Roberts JA, Lipman J (2013) Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 39:2070–2082PubMedCrossRef Udy AA, Roberts JA, Lipman J (2013) Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 39:2070–2082PubMedCrossRef
12.
go back to reference Hahn J, Choi JH, Chang MJ, (2017) Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients. J Clin Pharm Ther 42(6):661–671PubMedCrossRef Hahn J, Choi JH, Chang MJ, (2017) Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients. J Clin Pharm Ther 42(6):661–671PubMedCrossRef
13.
go back to reference Jamal JA, Mueller BA, Choi GY, Lipman J, Roberts JA (2015) How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis 82:92–103PubMedCrossRef Jamal JA, Mueller BA, Choi GY, Lipman J, Roberts JA (2015) How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis 82:92–103PubMedCrossRef
14.
go back to reference Abdul-Aziz MH, Roberts JA (2020) Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter? Curr Opin Anaesthesiol 33:71–82PubMedCrossRef Abdul-Aziz MH, Roberts JA (2020) Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter? Curr Opin Anaesthesiol 33:71–82PubMedCrossRef
15.
go back to reference Ha MA, Sieg AC (2017) Evaluation of altered drug pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation. Pharmacotherapy 37:221–235PubMedCrossRef Ha MA, Sieg AC (2017) Evaluation of altered drug pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation. Pharmacotherapy 37:221–235PubMedCrossRef
16.
go back to reference Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, Study D (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083PubMedCrossRef Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, Study D (2014) DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083PubMedCrossRef
17.
go back to reference Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10PubMedCrossRef Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10PubMedCrossRef
18.
go back to reference Abdul-Aziz MH, Brady K, Cotta MO, Roberts JA (2022) Therapeutic drug monitoring of antibiotics: defining the therapeutic range. Ther Drug Monit 44:19–31PubMedCrossRef Abdul-Aziz MH, Brady K, Cotta MO, Roberts JA (2022) Therapeutic drug monitoring of antibiotics: defining the therapeutic range. Ther Drug Monit 44:19–31PubMedCrossRef
19.
go back to reference Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network T, Participating NF (2013) Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol 34:1–14PubMedCrossRef Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network T, Participating NF (2013) Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol 34:1–14PubMedCrossRef
20.
go back to reference Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J (2018) MIC-based dose adjustment: facts and fables. J Antimicrob Chemother 73:564–568PubMedCrossRef Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J (2018) MIC-based dose adjustment: facts and fables. J Antimicrob Chemother 73:564–568PubMedCrossRef
21.
go back to reference Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honoré PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA (2015) Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 41:1411–1423PubMedCrossRef Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honoré PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA (2015) Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 41:1411–1423PubMedCrossRef
22.
go back to reference Bagshaw SM, Wald R, Adhikari NKJ, Bellomo R, da Costa BR, Dreyfuss D, Du B, Gallagher MP, Gaudry S, Hoste EA, Lamontagne F, Joannidis M, Landoni G, Liu KD, McAuley DF, McGuinness SP, Neyra JA, Nichol AD, Ostermann M, Palevsky PM, Pettilä V, Quenot JP, Qiu H, Rochwerg B, Schneider AG, Smith OM, Thomé F, Thorpe KE, Vaara S, Weir M, Wang AY, Young P, Zarbock A (2020) Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med 383:240–251PubMedCrossRef Bagshaw SM, Wald R, Adhikari NKJ, Bellomo R, da Costa BR, Dreyfuss D, Du B, Gallagher MP, Gaudry S, Hoste EA, Lamontagne F, Joannidis M, Landoni G, Liu KD, McAuley DF, McGuinness SP, Neyra JA, Nichol AD, Ostermann M, Palevsky PM, Pettilä V, Quenot JP, Qiu H, Rochwerg B, Schneider AG, Smith OM, Thomé F, Thorpe KE, Vaara S, Weir M, Wang AY, Young P, Zarbock A (2020) Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med 383:240–251PubMedCrossRef
23.
go back to reference Zhang L, Yang J, Eastwood GM, Zhu G, Tanaka A, Bellomo R (2015) Extended daily dialysis versus continuous renal replacement therapy for acute kidney injury: a meta-analysis. Am J Kidney Dis 66:322–330PubMedCrossRef Zhang L, Yang J, Eastwood GM, Zhu G, Tanaka A, Bellomo R (2015) Extended daily dialysis versus continuous renal replacement therapy for acute kidney injury: a meta-analysis. Am J Kidney Dis 66:322–330PubMedCrossRef
24.
go back to reference Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, Ferrari F, Guggia S, Joannidis M, Kellum J, Kim JC, Mehta RL, Ricci Z, Trevisani A, Marafon S, Clark WR, Vincent JL, Ronco C (2016) Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care 20:318PubMedPubMedCentralCrossRef Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, Ferrari F, Guggia S, Joannidis M, Kellum J, Kim JC, Mehta RL, Ricci Z, Trevisani A, Marafon S, Clark WR, Vincent JL, Ronco C (2016) Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care 20:318PubMedPubMedCentralCrossRef
25.
go back to reference Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ (2018) Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother 62(5):e02497–17 Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ (2018) Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother 62(5):e02497–17
26.
go back to reference Roger C, Muller L, Wallis SC, Louart B, Saissi G, Lipman J, Lefrant JY, Roberts JA (2016) Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemother 71:464–470PubMedCrossRef Roger C, Muller L, Wallis SC, Louart B, Saissi G, Lipman J, Lefrant JY, Roberts JA (2016) Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemother 71:464–470PubMedCrossRef
27.
go back to reference Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Lefrant JY, Roberts JA (2016) Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother 60:4901–4909PubMedPubMedCentralCrossRef Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Lefrant JY, Roberts JA (2016) Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother 60:4901–4909PubMedPubMedCentralCrossRef
28.
go back to reference Jamal JA, Udy AA, Lipman J, Roberts JA (2014) The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. Crit Care Med 42:1640–1650PubMedCrossRef Jamal JA, Udy AA, Lipman J, Roberts JA (2014) The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. Crit Care Med 42:1640–1650PubMedCrossRef
29.
go back to reference Barrasa H, Soraluce A, Isla A, Martín A, Maynar J, Canut A, Sánchez-Izquierdo JA, Rodríguez-Gascón A (2019) Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment. J Crit Care 50:69–76PubMedCrossRef Barrasa H, Soraluce A, Isla A, Martín A, Maynar J, Canut A, Sánchez-Izquierdo JA, Rodríguez-Gascón A (2019) Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment. J Crit Care 50:69–76PubMedCrossRef
30.
go back to reference Ulldemolins M, Soy D, Llaurado-Serra M, Vaquer S, Castro P, Rodríguez AH, Pontes C, Calvo G, Torres A, Martín-Loeches I (2015) Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother 59:5520–5528PubMedPubMedCentralCrossRef Ulldemolins M, Soy D, Llaurado-Serra M, Vaquer S, Castro P, Rodríguez AH, Pontes C, Calvo G, Torres A, Martín-Loeches I (2015) Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother 59:5520–5528PubMedPubMedCentralCrossRef
31.
go back to reference Lee BV, Fong G, Bolaris M, Neely M, Minejima E, Kang A, Lee G, Gong CL (2021) Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin. Clin Microbiol Infect 27:1346.e1341-1346.e1347 Lee BV, Fong G, Bolaris M, Neely M, Minejima E, Kang A, Lee G, Gong CL (2021) Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin. Clin Microbiol Infect 27:1346.e1341-1346.e1347
32.
go back to reference Wicha SG, Märtson AG, Nielsen EI, Koch BCP, Friberg LE, Alffenaar JW, Minichmayr IK (2021) From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther 109:928–941PubMedCrossRef Wicha SG, Märtson AG, Nielsen EI, Koch BCP, Friberg LE, Alffenaar JW, Minichmayr IK (2021) From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther 109:928–941PubMedCrossRef
33.
go back to reference Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–851PubMedCrossRef Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–851PubMedCrossRef
34.
go back to reference Bartlett RH, Gattinoni L (2010) Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiol 76:534–540PubMed Bartlett RH, Gattinoni L (2010) Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiol 76:534–540PubMed
35.
36.
go back to reference Shekar K, Roberts JA, McDonald CI, Fisquet S, Barnett AG, Mullany DV, Ghassabian S, Wallis SC, Fung YL, Smith MT, Fraser JF (2012) Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care 16:R194PubMedPubMedCentralCrossRef Shekar K, Roberts JA, McDonald CI, Fisquet S, Barnett AG, Mullany DV, Ghassabian S, Wallis SC, Fung YL, Smith MT, Fraser JF (2012) Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care 16:R194PubMedPubMedCentralCrossRef
37.
go back to reference Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D (2010) Determinants of drug absorption in different ECMO circuits. Intensive Care Med 36:2109–2116PubMedPubMedCentralCrossRef Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D (2010) Determinants of drug absorption in different ECMO circuits. Intensive Care Med 36:2109–2116PubMedPubMedCentralCrossRef
38.
go back to reference Raffaeli G, Pokorna P, Allegaert K, Mosca F, Cavallaro G, Wildschut ED, Tibboel D (2019) Drug disposition and pharmacotherapy in neonatal ECMO: from fragmented data to integrated knowledge. Front Pediatr 7:360PubMedPubMedCentralCrossRef Raffaeli G, Pokorna P, Allegaert K, Mosca F, Cavallaro G, Wildschut ED, Tibboel D (2019) Drug disposition and pharmacotherapy in neonatal ECMO: from fragmented data to integrated knowledge. Front Pediatr 7:360PubMedPubMedCentralCrossRef
39.
go back to reference Park J, Shin DA, Lee S, Cho YJ, Jheon S, Lee JC, Kim HC (2017) Investigation of key circuit constituents affecting drug sequestration during extracorporeal membrane oxygenation treatment. ASAIO J 63:293–298PubMedCrossRef Park J, Shin DA, Lee S, Cho YJ, Jheon S, Lee JC, Kim HC (2017) Investigation of key circuit constituents affecting drug sequestration during extracorporeal membrane oxygenation treatment. ASAIO J 63:293–298PubMedCrossRef
40.
go back to reference Lemaitre F, Hasni N, Leprince P, Corvol E, Belhabib G, Fillâtre P, Luyt CE, Leven C, Farinotti R, Fernandez C, Combes A (2015) Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit Care 19:40PubMedPubMedCentralCrossRef Lemaitre F, Hasni N, Leprince P, Corvol E, Belhabib G, Fillâtre P, Luyt CE, Leven C, Farinotti R, Fernandez C, Combes A (2015) Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit Care 19:40PubMedPubMedCentralCrossRef
41.
go back to reference Shekar K, Roberts JA, Barnett AG, Diab S, Wallis SC, Fung YL, Fraser JF (2015) Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models. Crit Care 19:437PubMedPubMedCentralCrossRef Shekar K, Roberts JA, Barnett AG, Diab S, Wallis SC, Fung YL, Fraser JF (2015) Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models. Crit Care 19:437PubMedPubMedCentralCrossRef
42.
go back to reference Spriet I, Annaert P, Meersseman P, Hermans G, Meersseman W, Verbesselt R, Willems L (2009) Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 63:767–770PubMedCrossRef Spriet I, Annaert P, Meersseman P, Hermans G, Meersseman W, Verbesselt R, Willems L (2009) Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 63:767–770PubMedCrossRef
43.
go back to reference Preston TJ, Ratliff TM, Gomez D, Olshove VE Jr, Nicol KK, Sargel CL, Chicoine LG (2010) Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. J Extra Corpor Technol 42:199–202PubMedPubMedCentral Preston TJ, Ratliff TM, Gomez D, Olshove VE Jr, Nicol KK, Sargel CL, Chicoine LG (2010) Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. J Extra Corpor Technol 42:199–202PubMedPubMedCentral
44.
go back to reference Bhatt-Meht V, Annich G (2005) Sedative clearance during extracorporeal membrane oxygenation. Perfusion 20:309–315PubMedCrossRef Bhatt-Meht V, Annich G (2005) Sedative clearance during extracorporeal membrane oxygenation. Perfusion 20:309–315PubMedCrossRef
45.
go back to reference Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH (2007) Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med 33:1018–1024PubMedCrossRef Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH (2007) Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med 33:1018–1024PubMedCrossRef
46.
go back to reference Harthan AA, Buckley KW, Heger ML, Fortuna RS, Mays K (2014) Medication adsorption into contemporary extracorporeal membrane oxygenator circuits. J Pediatr Pharmacol Ther 19:288–295PubMedPubMedCentral Harthan AA, Buckley KW, Heger ML, Fortuna RS, Mays K (2014) Medication adsorption into contemporary extracorporeal membrane oxygenator circuits. J Pediatr Pharmacol Ther 19:288–295PubMedPubMedCentral
47.
go back to reference Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R (2020) Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther 215:107627PubMedPubMedCentralCrossRef Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R (2020) Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther 215:107627PubMedPubMedCentralCrossRef
48.
go back to reference Chen YC, Tsai FC, Fang JT, Yang CW (2014) Acute kidney injury in adults receiving extracorporeal membrane oxygenation. J Formos Med Assoc 113:778–785PubMedCrossRef Chen YC, Tsai FC, Fang JT, Yang CW (2014) Acute kidney injury in adults receiving extracorporeal membrane oxygenation. J Formos Med Assoc 113:778–785PubMedCrossRef
49.
go back to reference Watt KM, Cohen-Wolkowiez M, Barrett JS, Sevestre M, Zhao P, Brouwer KLR, Edginton AN (2018) Physiologically based pharmacokinetic approach to determine dosing on extracorporeal life support: fluconazole in children on ECMO. CPT Pharmacometrics Syst Pharmacol 7:629–637PubMedPubMedCentralCrossRef Watt KM, Cohen-Wolkowiez M, Barrett JS, Sevestre M, Zhao P, Brouwer KLR, Edginton AN (2018) Physiologically based pharmacokinetic approach to determine dosing on extracorporeal life support: fluconazole in children on ECMO. CPT Pharmacometrics Syst Pharmacol 7:629–637PubMedPubMedCentralCrossRef
50.
go back to reference Autmizguine J, Hornik CP, Benjamin DK Jr, Brouwer KL, Hupp SR, Cohen-Wolkowiez M, Watt KM (2016) Pharmacokinetics and safety of micafungin in infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J 35:1204–1210PubMedPubMedCentralCrossRef Autmizguine J, Hornik CP, Benjamin DK Jr, Brouwer KL, Hupp SR, Cohen-Wolkowiez M, Watt KM (2016) Pharmacokinetics and safety of micafungin in infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J 35:1204–1210PubMedPubMedCentralCrossRef
51.
go back to reference Watt KM, Benjamin DK Jr, Cheifetz IM, Moorthy G, Wade KC, Smith PB, Brouwer KL, Capparelli EV, Cohen-Wolkowiez M (2012) Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J 31:1042–1047PubMedPubMedCentralCrossRef Watt KM, Benjamin DK Jr, Cheifetz IM, Moorthy G, Wade KC, Smith PB, Brouwer KL, Capparelli EV, Cohen-Wolkowiez M (2012) Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J 31:1042–1047PubMedPubMedCentralCrossRef
52.
go back to reference Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G (1993) Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 15:263–266PubMedCrossRef Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G (1993) Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 15:263–266PubMedCrossRef
53.
go back to reference Kim YK, Kim HS, Park S, Kim HI, Lee SH, Lee DH (2022) Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation. J Antimicrob Chemother 77:1353–1364PubMedPubMedCentralCrossRef Kim YK, Kim HS, Park S, Kim HI, Lee SH, Lee DH (2022) Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation. J Antimicrob Chemother 77:1353–1364PubMedPubMedCentralCrossRef
54.
go back to reference Alihodzic D, Wicha SG, Frey OR, König C, Baehr M, Jarczak D, Kluge S, Langebrake C (2022) Ciprofloxacin in patients undergoing extracorporeal membrane oxygenation (ECMO): a population pharmacokinetic study. Pharmaceutics 14(5):965PubMedPubMedCentralCrossRef Alihodzic D, Wicha SG, Frey OR, König C, Baehr M, Jarczak D, Kluge S, Langebrake C (2022) Ciprofloxacin in patients undergoing extracorporeal membrane oxygenation (ECMO): a population pharmacokinetic study. Pharmaceutics 14(5):965PubMedPubMedCentralCrossRef
55.
go back to reference Kois AK, Gluck JA, Nicolau DP, Kuti JL (2022) Pharmacokinetics and time above the MIC exposure of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (ECMO). Int J Antimicrob Agents 60:106603PubMedCrossRef Kois AK, Gluck JA, Nicolau DP, Kuti JL (2022) Pharmacokinetics and time above the MIC exposure of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (ECMO). Int J Antimicrob Agents 60:106603PubMedCrossRef
56.
go back to reference Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Cho YJ, Corley A, Diehl A, Gilder E, Jakob SM, Kim HS, Levkovich BJ, Lim SY, McGuinness S, Parke R, Pellegrino V, Que YA, Reynolds C, Rudham S, Wallis SC, Welch SA, Zacharias D, Fraser JF, Shekar K, Roberts JA, Investigators AE (2022) Population pharmacokinetics of vancomycin in critically ill adult patients receiving extracorporeal membrane oxygenation (an ASAP ECMO Study). Antimicrob Agents Chemother 66:e0137721PubMedCrossRef Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Cho YJ, Corley A, Diehl A, Gilder E, Jakob SM, Kim HS, Levkovich BJ, Lim SY, McGuinness S, Parke R, Pellegrino V, Que YA, Reynolds C, Rudham S, Wallis SC, Welch SA, Zacharias D, Fraser JF, Shekar K, Roberts JA, Investigators AE (2022) Population pharmacokinetics of vancomycin in critically ill adult patients receiving extracorporeal membrane oxygenation (an ASAP ECMO Study). Antimicrob Agents Chemother 66:e0137721PubMedCrossRef
57.
go back to reference Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Cho YJ, Corley A, Gilder E, Kim HS, Lim SY, McGuinness S, Parke R, Reynolds C, Rudham S, Wallis SC, Welch SA, Fraser JF, Shekar K, Roberts JA (2022) Population pharmacokinetics and dosing simulations of ceftriaxone in critically ill patients receiving extracorporeal membrane oxygenation (An ASAP ECMO Study). Clin Pharmacokinet 61(6):847–856 Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Cho YJ, Corley A, Gilder E, Kim HS, Lim SY, McGuinness S, Parke R, Reynolds C, Rudham S, Wallis SC, Welch SA, Fraser JF, Shekar K, Roberts JA (2022) Population pharmacokinetics and dosing simulations of ceftriaxone in critically ill patients receiving extracorporeal membrane oxygenation (An ASAP ECMO Study). Clin Pharmacokinet 61(6):847–856
58.
go back to reference Jung Y, Lee DH, Kim HS (2021) Prospective cohort study of population pharmacokinetics and pharmacodynamic target attainment of vancomycin in adults on extracorporeal membrane oxygenation. Antimicrob Agents Chemother 65(2):e02408–20 Jung Y, Lee DH, Kim HS (2021) Prospective cohort study of population pharmacokinetics and pharmacodynamic target attainment of vancomycin in adults on extracorporeal membrane oxygenation. Antimicrob Agents Chemother 65(2):e02408–20
59.
go back to reference Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Corley A, Diehl A, Jakob SM, Levkovich BJ, Pellegrino V, Que YA, Reynolds C, Rudham S, Wallis SC, Welch SA, Zacharias D, Roberts JA, Shekar K, Fraser JF (2021) Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). Int J Antimicrob Agents 58:106466PubMedCrossRef Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Corley A, Diehl A, Jakob SM, Levkovich BJ, Pellegrino V, Que YA, Reynolds C, Rudham S, Wallis SC, Welch SA, Zacharias D, Roberts JA, Shekar K, Fraser JF (2021) Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). Int J Antimicrob Agents 58:106466PubMedCrossRef
60.
go back to reference Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Cho YJ, Corley A, Diehl A, Gilder E, Jakob SM, Kim HS, Levkovich BJ, Lim SY, McGuinness S, Parke R, Pellegrino V, Que YA, Reynolds C, Rudham S, Wallis SC, Welch SA, Zacharias D, Fraser JF, Shekar K, Roberts JA, Investigators AE (2021) Population Pharmacokinetics of piperacillin and tazobactam in critically ill patients receiving extracorporeal membrane oxygenation: an ASAP ECMO Study. Antimicrob Agents Chemother 65:e0143821PubMedCrossRef Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Cho YJ, Corley A, Diehl A, Gilder E, Jakob SM, Kim HS, Levkovich BJ, Lim SY, McGuinness S, Parke R, Pellegrino V, Que YA, Reynolds C, Rudham S, Wallis SC, Welch SA, Zacharias D, Fraser JF, Shekar K, Roberts JA, Investigators AE (2021) Population Pharmacokinetics of piperacillin and tazobactam in critically ill patients receiving extracorporeal membrane oxygenation: an ASAP ECMO Study. Antimicrob Agents Chemother 65:e0143821PubMedCrossRef
61.
go back to reference Gijsen M, Dreesen E, Annaert P, Nicolai J, Debaveye Y, Wauters J, Spriet I (2021) Meropenem pharmacokinetics and target attainment in critically ill patients are not affected by extracorporeal membrane oxygenation: a matched cohort analysis. Microorganisms 9(6):1310 Gijsen M, Dreesen E, Annaert P, Nicolai J, Debaveye Y, Wauters J, Spriet I (2021) Meropenem pharmacokinetics and target attainment in critically ill patients are not affected by extracorporeal membrane oxygenation: a matched cohort analysis. Microorganisms 9(6):1310
62.
go back to reference Van Daele R, Bekkers B, Lindfors M, Broman LM, Schauwvlieghe A, Rijnders B, Hunfeld NGM, Juffermans NP, Taccone FS, Coimbra Sousa CA, Jacquet LM, Laterre PF, Nulens E, Grootaert V, Lyster H, Reed A, Patel B, Meersseman P, Debaveye Y, Wauters J, Vandenbriele C, Spriet I (2021) A large retrospective assessment of voriconazole exposure in patients treated with extracorporeal membrane oxygenation. Microorganisms 9(7):1543 Van Daele R, Bekkers B, Lindfors M, Broman LM, Schauwvlieghe A, Rijnders B, Hunfeld NGM, Juffermans NP, Taccone FS, Coimbra Sousa CA, Jacquet LM, Laterre PF, Nulens E, Grootaert V, Lyster H, Reed A, Patel B, Meersseman P, Debaveye Y, Wauters J, Vandenbriele C, Spriet I (2021) A large retrospective assessment of voriconazole exposure in patients treated with extracorporeal membrane oxygenation. Microorganisms 9(7):1543
63.
go back to reference Touchard C, Aubry A, Eloy P, Brechot N, Lebreton G, Franchineau G, Besset S, Hekimian G, Nieszkowska A, Leprince P, Luyt CE, Combes A, Schmidt M (2018) Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation. Crit Care 22:199PubMedPubMedCentralCrossRef Touchard C, Aubry A, Eloy P, Brechot N, Lebreton G, Franchineau G, Besset S, Hekimian G, Nieszkowska A, Leprince P, Luyt CE, Combes A, Schmidt M (2018) Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation. Crit Care 22:199PubMedPubMedCentralCrossRef
64.
go back to reference Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Corley A, Diehl A, Levkovich BJ, Pellegrino V, Reynolds C, Rudham S, Wallis SC, Welch SA, Roberts JA, Shekar K, Fraser JF (2022) Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). Anaesth Crit Care Pain Med 41:101080PubMedCrossRef Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Corley A, Diehl A, Levkovich BJ, Pellegrino V, Reynolds C, Rudham S, Wallis SC, Welch SA, Roberts JA, Shekar K, Fraser JF (2022) Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). Anaesth Crit Care Pain Med 41:101080PubMedCrossRef
65.
go back to reference Sinnah F, Shekar K, Abdul-Aziz MH, Buscher H, Diab SD, Fisquet S, Fung YL, McDonald CI, Reynolds C, Rudham S, Wallis SC, Welch S, Xie J, Fraser JF, Roberts JA, investigators AE (2017) Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation. Crit Care Resusc 19:8–14PubMed Sinnah F, Shekar K, Abdul-Aziz MH, Buscher H, Diab SD, Fisquet S, Fung YL, McDonald CI, Reynolds C, Rudham S, Wallis SC, Welch S, Xie J, Fraser JF, Roberts JA, investigators AE (2017) Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation. Crit Care Resusc 19:8–14PubMed
66.
go back to reference Shekar K, Roberts JA, McDonald CI, Ghassabian S, Anstey C, Wallis SC, Mullany DV, Fung YL, Fraser JF (2015) Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care 19:164PubMedPubMedCentralCrossRef Shekar K, Roberts JA, McDonald CI, Ghassabian S, Anstey C, Wallis SC, Mullany DV, Fung YL, Fraser JF (2015) Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care 19:164PubMedPubMedCentralCrossRef
67.
go back to reference Shekar K, Roberts JA, Smith MT, Fung YL, Fraser JF (2013) The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiol 13:7PubMedPubMedCentralCrossRef Shekar K, Roberts JA, Smith MT, Fung YL, Fraser JF (2013) The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiol 13:7PubMedPubMedCentralCrossRef
68.
go back to reference Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, Ghassabian S, Wallis SC, Levkovich B, Pellegrino V, McGuinness S, Parke R, Gilder E, Barnett AG, Walsham J, Mullany DV, Fung YL, Smith MT, Fraser JF (2012) ASAP ECMO: antibiotic, sedative and analgesic pharmacokinetics during extracorporeal membrane oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol 12:29PubMedPubMedCentralCrossRef Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, Ghassabian S, Wallis SC, Levkovich B, Pellegrino V, McGuinness S, Parke R, Gilder E, Barnett AG, Walsham J, Mullany DV, Fung YL, Smith MT, Fraser JF (2012) ASAP ECMO: antibiotic, sedative and analgesic pharmacokinetics during extracorporeal membrane oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol 12:29PubMedPubMedCentralCrossRef
69.
go back to reference Cies JJ, Moore WS 2nd, Conley SB, Dickerman MJ, Small C, Carella D, Shea P, Parker J, Chopra A (2016) Pharmacokinetics of continuous infusion meropenem with concurrent extracorporeal life support and continuous renal replacement therapy: a case report. J Pediatr Pharmacol Ther 21:92–97PubMedPubMedCentral Cies JJ, Moore WS 2nd, Conley SB, Dickerman MJ, Small C, Carella D, Shea P, Parker J, Chopra A (2016) Pharmacokinetics of continuous infusion meropenem with concurrent extracorporeal life support and continuous renal replacement therapy: a case report. J Pediatr Pharmacol Ther 21:92–97PubMedPubMedCentral
70.
go back to reference Nordmann P, Picazo JJ, Mutters R, Korten V, Quintana A, Laeuffer JM, Seak JC, Flamm RK, Morrissey I (2011) Comparative activity of carbapenem testing: the COMPACT study. J Antimicrob Chemother 66:1070–1078PubMedCrossRef Nordmann P, Picazo JJ, Mutters R, Korten V, Quintana A, Laeuffer JM, Seak JC, Flamm RK, Morrissey I (2011) Comparative activity of carbapenem testing: the COMPACT study. J Antimicrob Chemother 66:1070–1078PubMedCrossRef
71.
go back to reference McKinnon PS, Paladino JA, Schentag JJ (2008) Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345–351PubMedCrossRef McKinnon PS, Paladino JA, Schentag JJ (2008) Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345–351PubMedCrossRef
72.
go back to reference Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43:925–942PubMedCrossRef Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ (2004) Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 43:925–942PubMedCrossRef
73.
go back to reference Imani S, Alffenaar JW, Cotta MO, Daveson K, van Hal S, Lau C, Marriott D, Penm J, Roberts JA, Tabah A, Trethewy N, Williams P, Sandaradura I (2020) Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices. Int J Antimicrob Agents, 56(6):106180 Imani S, Alffenaar JW, Cotta MO, Daveson K, van Hal S, Lau C, Marriott D, Penm J, Roberts JA, Tabah A, Trethewy N, Williams P, Sandaradura I (2020) Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices. Int J Antimicrob Agents, 56(6):106180
74.
go back to reference Tabah A, De Waele J, Lipman J, Zahar JR, Cotta MO, Barton G, Timsit JF, Roberts JA, Working Group for Antimicrobial Use in the ICUwtISotESoICM (2015) The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother 70:2671–2677PubMedCrossRef Tabah A, De Waele J, Lipman J, Zahar JR, Cotta MO, Barton G, Timsit JF, Roberts JA, Working Group for Antimicrobial Use in the ICUwtISotESoICM (2015) The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother 70:2671–2677PubMedCrossRef
75.
go back to reference Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377PubMedCrossRef Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377PubMedCrossRef
76.
go back to reference Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedCrossRef Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedCrossRef
77.
go back to reference Ates HC, Roberts JA, Lipman J, Cass AEG, Urban GA, Dincer C (2020) On-site therapeutic drug monitoring. Trends Biotechnol 38:1262–1277PubMedCrossRef Ates HC, Roberts JA, Lipman J, Cass AEG, Urban GA, Dincer C (2020) On-site therapeutic drug monitoring. Trends Biotechnol 38:1262–1277PubMedCrossRef
78.
go back to reference Rawson TM, O’Hare D, Herrero P, Sharma S, Moore LSP, de Barra E, Roberts JA, Gordon AC, Hope W, Georgiou P, Cass AEG, Holmes AH (2018) Delivering precision antimicrobial therapy through closed-loop control systems. J Antimicrob Chemother 73:835–843PubMedCrossRef Rawson TM, O’Hare D, Herrero P, Sharma S, Moore LSP, de Barra E, Roberts JA, Gordon AC, Hope W, Georgiou P, Cass AEG, Holmes AH (2018) Delivering precision antimicrobial therapy through closed-loop control systems. J Antimicrob Chemother 73:835–843PubMedCrossRef
79.
go back to reference Visser EWA, Yan J, van IJzendoorn LJ, Prins MWJ (2018) Continuous biomarker monitoring by particle mobility sensing with single molecule resolution. Nat Commun 9:2541PubMedPubMedCentralCrossRef Visser EWA, Yan J, van IJzendoorn LJ, Prins MWJ (2018) Continuous biomarker monitoring by particle mobility sensing with single molecule resolution. Nat Commun 9:2541PubMedPubMedCentralCrossRef
80.
go back to reference Bian S, Zhu B, Rong G, Sawan M (2021) Towards wearable and implantable continuous drug monitoring: a review. J Pharm Anal 11:1–14PubMedCrossRef Bian S, Zhu B, Rong G, Sawan M (2021) Towards wearable and implantable continuous drug monitoring: a review. J Pharm Anal 11:1–14PubMedCrossRef
81.
go back to reference Heil EL, Nicolau DP, Farkas A, Roberts JA, Thom KA (2018) Pharmacodynamic target attainment for cefepime, meropenem, and piperacillin-tazobactam using a pharmacokinetic/pharmacodynamic-based dosing calculator in critically ill patients. Antimicrob Agents Chemother 62(9):e01008–18 Heil EL, Nicolau DP, Farkas A, Roberts JA, Thom KA (2018) Pharmacodynamic target attainment for cefepime, meropenem, and piperacillin-tazobactam using a pharmacokinetic/pharmacodynamic-based dosing calculator in critically ill patients. Antimicrob Agents Chemother 62(9):e01008–18
Metadata
Title
Machines that help machines to help patients: optimising antimicrobial dosing in patients receiving extracorporeal membrane oxygenation and renal replacement therapy using dosing software
Authors
Jason A. Roberts
Rinaldo Bellomo
Menino O. Cotta
Birgit C. P. Koch
Haifa Lyster
Marlies Ostermann
Claire Roger
Kiran Shekar
Kevin Watt
Mohd H. Abdul-Aziz
Publication date
23-08-2022
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 10/2022
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-022-06847-2

Other articles of this Issue 10/2022

Intensive Care Medicine 10/2022 Go to the issue